Singapore markets closed

UroGen Pharma Ltd. (0XOD.L)

LSE - LSE Delayed Price. Currency in USD
Add to watchlist
8.01-0.49 (-5.76%)
At close: 07:29PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.76
52-week change 3N/A
S&P500 52-week change 3-13.21%
52-week high 30.00
52-week low 30.00
50-day moving average 3N/A
200-day moving average 3N/A

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 516.1M
Implied shares outstanding 6N/A
Float 817.96M
% held by insiders 110.12%
% held by institutions 170.20%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)31 Dec 2022

Profitability

Profit margin -169.62%
Operating margin (ttm)-122.82%

Management effectiveness

Return on assets (ttm)N/A
Return on equity (ttm)N/A

Income statement

Revenue (ttm)64.36M
Revenue per share (ttm)2.82
Quarterly revenue growth (yoy)11.90%
Gross profit (ttm)56.7M
EBITDA -78.12M
Net income avi to common (ttm)-109.16M
Diluted EPS (ttm)-5.05
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)95.91M
Total cash per share (mrq)4.15
Total debt (mrq)74.67M
Total debt/equity (mrq)N/A
Current ratio (mrq)N/A
Book value per share (mrq)-2.75

Cash flow statement

Operating cash flow (ttm)N/A
Levered free cash flow (ttm)N/A